PSTV

Plus Therapeutics Inc (PSTV) | Rumor.io

Plus Therapeutics

PSTV

Attention (50-day avg)0%

Attention rank (50-day avg)#4,121

Bullish sentiment (50-day avg)52%

Price to earnings ratio0.18

Market capitalization26.4M

Earnings per share21.6

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-22.4M

Social

What share of all stock conversation is about PSTV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.01% 0

Jul 14

$PSTV has been highlighted in the recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for CNS Cancers, including guidance relevant to leptomeningeal metastases.
The updated NCCN guidelines continue to support the importance of CSF analysis in the diagnosis and management of leptomeningeal metastases, including the role of CNSide in monitoring these conditions.
$PSTV has also seen expanding U.S. payer coverage, including Elevance Health and Blue Shield of California, as well as Medicare enrollment and CAP accreditation, reinforcing its clinical role in leptomeningeal metastases monitoring.

Generated by AI

Sentiment

Of the messages about PSTV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	83.45% +0.04
Bearish	—	—	—	16.55% -0.04

Bullish· Apr 21

$PSTV has the potential to double in value, similar to a previous call that doubled in mere days.
The short ratio for $PSTV is decreasing daily, and with positive news, the stock is expected to explode in value.
Buying and holding $PSTV is a good strategy, as the stock is expected to experience a significant squeeze, allowing shorts to cover their positions within 10 days.

Bearish· Jun 15

The company is facing a potential dilution event, which could negatively impact shareholders.
The stock's chart is showing negative trends over the past 10 years, 5 years, 1 year, 6 months, 1 month, and 1 week, setting up a perfect scenario for a significant price drop.
The company's floor may not be as secure as previously thought, and shareholders may be required to add more money to their accounts, potentially leading to further losses.

Generated by AI

Topics

Of the messages about PSTV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	1.38%
Technical Analysis	—	—	—	0.84%
Macro	—	—	—	49.25%
Analysts	—	—	—	48.25%
Controversies	—	—	—	0%
Earnings	—	—	—	0.28%

Announcements· Nov 20

Plus Therapeutics, Inc. (PSTV) has signed a national agreement with Humana, Inc. (HUM) to provide the CNSide Cerebrospinal Fluid Tumor Cell Enumeration lab developed test, covering approximately 16 million people in the US.
This agreement brings the total policy coverage for CNSide CSF Tumor Cell Enumeration laboratory developed test to 67 million people, representing around 20% of the US market.
The national coverage agreement is expected to boost revenue for PSTV and set the stage for real-world access in metastatic CNS cancer, with the lab now being CLIA-certified and compliant.

Technical Analysis· Apr 10

$PSTV has decisively breached the $4.31 resistance, confirming a high-momentum technical breakout with an initial target of $6.59.
The stock's +26.02% surge on 1.17M volume suggests strong momentum, with a new executive appointment fueling the move and a technical target of $6.59 in play.
A clean upside move is underway, with volume supporting the move and price trending higher, and a technical target aligning at $7.12.

Generated by AI

Community

Of the messages about PSTV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	18.59%
Newcomers	—	—	100%	81.41%

Regulars· Jan 14

The stock price of $PSTV dropped approximately 38% after the company announced a public offering of $15 million, with the stock price falling to $0.29.
The management of Plus Therapeutics is trying to avoid reverse stock split (RS) and has taken steps to minimize its impact, as they believe it could negatively affect the stock price.
The proceeds from the public offering will be used to support the company's radiopharmaceutical CNS cancer programs, with a 30-day over-allotment option available.

Newcomers· Apr 10

Newcomers are focusing on the appointment of Dr. Eric J. Daniels as a key catalyst for Plus Therapeutics' growth, strengthening clinical and regulatory execution.
The surge in Plus Therapeutics' stock price (+24.23% to $4.87) is seen as a sign of strategic execution, with the new CMO appointment directly supporting market share expansion.
The technical breakout of Plus Therapeutics' stock, clearing the $4.36 resistance, is confirmed by high volume and institutional conviction, with a measured target of $6.93.

Generated by AI

Formerly known as Plus Therapeutics, Cerenome integrates precision diagnostics, targeted therapeutics, and artificial intelligence to improve how CNS cancers are detected, treated, and understoodHOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective August 3, 2026, the Company’s name will become Cerenome, Inc. The Company's common stock will begin trading o

2mo agoYahoo Finance

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

Posters will highlight research across the Company’s REYOBIQ™ clinical development program and CNSide® cerebrospinal fluid diagnostic platformHOUSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing targeted therapeutics and diagnostics for central nervous system (“CNS”) cancers, today announced two posters highlighting its ReSPECT-LM clinical development program and CNSide® cerebrospinal fluid (“CSF”)

2mo agoYahoo Finance

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2 million people throughout Ohio and Kentucky, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to approximately 127

2mo agoYahoo Finance

CNSide Diagnostics signs coverage deal with Medical Mutual

2mo agoInvesting.com

Also Discussed

Investors talking about PSTV also mention

#	Name	Attention
1	AtlasClear Holdings, Inc.ATCH	0.01%0
2	Incannex Healthcare Inc.IXHL	0.01%0
3	Healthcare Triangle Inc.HCTI	0%0
4	Dragonfly Energy Holdings Corp.DFLI	0%0
5	Nvni Group LimitedNVNI	0%0
6	Phio Pharmaceuticals Corp.PHIO	0%new
7	Bit Origin Ltd. Class A Ordinary SharesBTOG	0%0
8	Intensity Therapeutics, Inc.INTS	0%0
9	Nuwellis, Inc.NUWE	0%+0
10	Oncolytics Biotech Inc.ONCY	0%0

Plus Therapeutics Inc

Healthcare
Biotechnology

Plus Therapeutics Inc is a clinical-stage pharmaceutical company specializing in the discovery, development, commercialization, and delivery of complex treatments for patients with cancer and rare diseases. The company concentrates on innovative, targeted radiotherapeutics for adults and children facing difficult-to-treat cancers, utilizing novel drug formulations and technologies to deliver a single, safe, and effective dose of radiation directly to the tumor. Its primary programs address recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers, with a key candidate being rhenium (186Re) obisbemeda designed specifically for central nervous system cancers. Operating within the biotechnology sector of healthcare, Plus Therapeutics Inc advances therapies aimed at improving outcomes in oncology and rare disease areas. Headquartered in Houston, Texas, the company focuses on precision medicine approaches to enhance treatment efficacy for challenging medical conditions.

Website

Location

6420 LEVIT GREEN BOULEVARD

Houston, TX, 77021

United States

Social

What share of all stock conversation is about PSTV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.01% 0

Jul 14

$PSTV has been highlighted in the recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for CNS Cancers, including guidance relevant to leptomeningeal metastases.
The updated NCCN guidelines continue to support the importance of CSF analysis in the diagnosis and management of leptomeningeal metastases, including the role of CNSide in monitoring these conditions.
$PSTV has also seen expanding U.S. payer coverage, including Elevance Health and Blue Shield of California, as well as Medicare enrollment and CAP accreditation, reinforcing its clinical role in leptomeningeal metastases monitoring.

Generated by AI

Sentiment

Of the messages about PSTV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	83.45% +0.04
Bearish	—	—	—	16.55% -0.04

Bullish· Apr 21

$PSTV has the potential to double in value, similar to a previous call that doubled in mere days.
The short ratio for $PSTV is decreasing daily, and with positive news, the stock is expected to explode in value.
Buying and holding $PSTV is a good strategy, as the stock is expected to experience a significant squeeze, allowing shorts to cover their positions within 10 days.

Bearish· Jun 15

The company is facing a potential dilution event, which could negatively impact shareholders.
The stock's chart is showing negative trends over the past 10 years, 5 years, 1 year, 6 months, 1 month, and 1 week, setting up a perfect scenario for a significant price drop.
The company's floor may not be as secure as previously thought, and shareholders may be required to add more money to their accounts, potentially leading to further losses.

Generated by AI

Topics

Of the messages about PSTV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	1.38%
Technical Analysis	—	—	—	0.84%
Macro	—	—	—	49.25%
Analysts	—	—	—	48.25%
Controversies	—	—	—	0%
Earnings	—	—	—	0.28%

Announcements· Nov 20

Plus Therapeutics, Inc. (PSTV) has signed a national agreement with Humana, Inc. (HUM) to provide the CNSide Cerebrospinal Fluid Tumor Cell Enumeration lab developed test, covering approximately 16 million people in the US.
This agreement brings the total policy coverage for CNSide CSF Tumor Cell Enumeration laboratory developed test to 67 million people, representing around 20% of the US market.
The national coverage agreement is expected to boost revenue for PSTV and set the stage for real-world access in metastatic CNS cancer, with the lab now being CLIA-certified and compliant.

Technical Analysis· Apr 10

$PSTV has decisively breached the $4.31 resistance, confirming a high-momentum technical breakout with an initial target of $6.59.
The stock's +26.02% surge on 1.17M volume suggests strong momentum, with a new executive appointment fueling the move and a technical target of $6.59 in play.
A clean upside move is underway, with volume supporting the move and price trending higher, and a technical target aligning at $7.12.

Generated by AI

Community

Of the messages about PSTV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	18.59%
Newcomers	—	—	100%	81.41%

Regulars· Jan 14

The stock price of $PSTV dropped approximately 38% after the company announced a public offering of $15 million, with the stock price falling to $0.29.
The management of Plus Therapeutics is trying to avoid reverse stock split (RS) and has taken steps to minimize its impact, as they believe it could negatively affect the stock price.
The proceeds from the public offering will be used to support the company's radiopharmaceutical CNS cancer programs, with a 30-day over-allotment option available.

Newcomers· Apr 10

Newcomers are focusing on the appointment of Dr. Eric J. Daniels as a key catalyst for Plus Therapeutics' growth, strengthening clinical and regulatory execution.
The surge in Plus Therapeutics' stock price (+24.23% to $4.87) is seen as a sign of strategic execution, with the new CMO appointment directly supporting market share expansion.
The technical breakout of Plus Therapeutics' stock, clearing the $4.36 resistance, is confirmed by high volume and institutional conviction, with a measured target of $6.93.

Generated by AI

Plus Therapeutics

Social

Jul 14

Bullish· Apr 21

Bearish· Jun 15

Announcements· Nov 20

Technical Analysis· Apr 10

Regulars· Jan 14

Newcomers· Apr 10

Cerenome Launches New Corporate Identity as Integrated CNS Oncology Company

CNSide Diagnostics signs coverage deal with HCSC for CSF assay

Cerenome Launches as an Integrated CNS Oncology Company

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

CNSide Diagnostics signs coverage deal with Medical Mutual

Also Discussed

Plus Therapeutics Inc

Company Information

Location

Cerenome Launches New Corporate Identity as Integrated CNS Oncology Company

CNSide Diagnostics signs coverage deal with HCSC for CSF assay

Cerenome Launches as an Integrated CNS Oncology Company

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

CNSide Diagnostics signs coverage deal with Medical Mutual

Also Discussed

Social

Jul 14

Bullish· Apr 21

Bearish· Jun 15

Announcements· Nov 20

Technical Analysis· Apr 10

Regulars· Jan 14

Newcomers· Apr 10